
Century Therapeutics, Inc.
94
Recent developments highlight Century Therapeutics’ clinical progress, financial reporting, leadership appointments, and analyst coverage.
- Century Therapeutics reported third quarter 2026 financial results, including a net loss reduction and maintained strong liquidity as of September 30, 2026 [N1][N2][S2].
- The company advanced CNTY-813 toward clinical testing with new data presented and IND submission on track for late 2026 [N3][N4].
- IECURE CEO Joseph Truitt was appointed to Century Therapeutics’ board as CNTY-813 nears IND filing [N4].
- Mizuho initiated coverage of Century Therapeutics with an outperform recommendation in May 2026 [N5].
- Initial data from the Phase 1/2 investigator-sponsored trial of CNTY-101 in B-cell-mediated autoimmune diseases was presented in December 2025 [S1].
Century Therapeutics, Inc. develops allogeneic pluripotent stem cell therapies using induced pluripotent stem cells (iPSCs) engineered with proprietary Allo-Evasion™ technology to treat autoimmune diseases such as type 1 diabetes (T1D) and cancers. The company’s platform enables scalable manufacturing of off-the-shelf cell therapies designed to overcome limitations of autologous approaches by providing consistent, readily available treatments. Its pipeline includes CNTY-813, an iPSC-derived beta islet cell replacement therapy for T1D, and CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases. CNTY-101, a CAR-iNK cell therapy, is in a Phase 1/2 investigator-sponsored trial for autoimmune diseases. The company emphasizes in-house manufacturing to reduce costs and improve quality. As of September 30, 2026, Century Therapeutics held $45.0 million in cash and equivalents and $72.2 million in short-term investments, with a strong liquidity position. The company reported a net loss of $23.5 million for Q3 2026.
Century Therapeutics, Inc. is a biotechnology company focused on developing off-the-shelf allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer. The company’s proprietary Allo-Evasion™ technology aims to prevent immune rejection and enable repeat dosing. Its lead candidate, CNTY-813, is an iPSC-derived beta islet cell therapy for type 1 diabetes, currently in IND-enabling studies with IND submission anticipated in 2026. The company reported a net loss of $23.5 million for Q3 2026 and maintains strong liquidity with a current ratio of 8.74 as of September 30, 2026. Recent developments include clinical progress on CNTY-813, board appointments, and positive analyst coverage. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Century Therapeutics leverages advanced iPSC technology and proprietary Allo-Evasion™ engineering to develop scalable, off-the-shelf cell therapies addressing significant unmet needs in autoimmune diseases and cancer. Its lead candidate CNTY-813 targets type 1 diabetes with the potential to restore insulin production without chronic immunosuppression. The company’s in-house manufacturing capabilities aim to reduce costs and improve product consistency. Positive clinical progress, regulatory milestones such as IND submissions, and strategic board appointments support its development trajectory. Analyst coverage with outperform recommendations reflects market recognition of its innovative platform and pipeline potential.
Risks include the inherent uncertainties of clinical development, regulatory approvals, and the ability to demonstrate safety and efficacy of novel allogeneic cell therapies. Manufacturing scale-up and maintaining product consistency pose operational challenges. The company reported ongoing net losses and depends on capital markets or partnerships for funding. Competitive pressures from other cell therapy developers and evolving treatment landscapes may impact market adoption. Potential immune rejection despite Allo-Evasion™ technology and unforeseen safety issues could affect clinical progress and commercialization prospects.
Century Therapeutics’ moat is based on its proprietary Allo-Evasion™ technology that aims to prevent immune rejection of allogeneic cell therapies, enabling repeat dosing and potentially reducing the need for immune suppression. Its use of induced pluripotent stem cells (iPSCs) allows for unlimited replication, extensive genetic editing, and scalable manufacturing, differentiating it from autologous and donor-derived therapies. The company’s integrated platform combining advanced gene editing, cell differentiation expertise, and in-house manufacturing capabilities supports consistent product quality and cost advantages. These factors collectively create barriers to entry and position Century Therapeutics as a leader in off-the-shelf allogeneic cell therapies for autoimmune diseases and cancer.
• Clinical and Regulatory Risk: The company’s therapies are in early clinical or IND-enabling stages, with inherent uncertainties in demonstrating safety and efficacy and obtaining regulatory approvals.
• Manufacturing and Scale-up Risk: Scaling manufacturing of complex iPSC-derived cell therapies with consistent quality and cost control presents operational challenges.
• Financial Risk: Century Therapeutics reported net losses and relies on external funding sources to support ongoing development and operations.
• Competitive Risk: The cell therapy field is competitive with multiple players developing alternative approaches that may impact market opportunities.
• Immunogenicity Risk: Despite proprietary Allo-Evasion™ technology, there remains risk of immune rejection or adverse immune responses affecting therapy durability and safety.
Business trends: Advancement of off-the-shelf allogeneic iPSC-derived cell therapies targeting autoimmune diseases and cancer, with focus on scalable manufacturing and proprietary immune evasion technology.
Execution milestones: IND submission and clinical initiation for CNTY-813 beta islet therapy, ongoing clinical data from CNTY-101 trial, and continued manufacturing scale-up.
Key risks: Clinical and regulatory uncertainties, manufacturing scale-up challenges, financial sustainability, competitive pressures, and potential immune rejection despite Allo-Evasion™ technology.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Century Therapeutics, Inc. is a biotechnology company developing allogeneic pluripotent stem cell therapies targeting autoimmune diseases including type 1 diabetes (T1D) and cancer [S1].
- The company’s platform uses induced pluripotent stem cells (iPSCs) which can self-renew indefinitely and differentiate into multiple cell types, enabling scalable manufacturing and genetic editing [S1].
- Century Therapeutics has proprietary Allo-Evasion™ technology designed to prevent immune rejection of its cell therapies, allowing for repeat dosing and potentially reducing or eliminating the need for immune suppression [S1].
- The company’s pipeline includes CNTY-813, an iPSC-derived beta islet cell replacement therapy for T1D engineered with Allo-Evasion™ 5.0, currently in IND-enabling studies with IND submission anticipated in 2026 [S1].
- CNTY-308 is a CD19-targeted CAR-iT cell therapy candidate for B-cell-mediated diseases, also engineered with Allo-Evasion™ 5.0, in IND-enabling studies [S1].
- CNTY-101 is a CAR-iNK cell therapy in a Phase 1/2 investigator-sponsored trial for B-cell-driven autoimmune diseases, with initial data presented in December 2025 [S1].
- The company emphasizes off-the-shelf therapies derived from healthy donors or engineered cell lines, aiming for scalability, availability, and consistent potency compared to autologous therapies [S1].
- Manufacturing is conducted in-house with a focus on scale, quality, and cost reduction [S1].
- T1D affects approximately nine million people worldwide, with current treatments relying on insulin replacement that does not address underlying causes; cell-based therapies like CNTY-813 aim to restore insulin production without chronic immunosuppression [S1].
- As of September 30, 2026, Century Therapeutics had $45.0 million in cash and equivalents, $72.2 million in short-term investments, total current assets of $122.7 million, and current liabilities of $14.0 million, resulting in a current ratio of 8.74 and cash ratio of 8.34 [S2].
- The company reported a net loss of $23.5 million and basic and diluted EPS of -$0.11 for the quarter ended September 30, 2026 [S2].
- Recent news highlights include reporting third quarter 2026 financial results, a decline in Q3 loss, advancement of CNTY-813 toward clinical testing, appointment of IECURE CEO Joseph Truitt to the board, and IND submission progress for CNTY-813 [N1][N2][N3][N4].
- Mizuho initiated coverage with an outperform recommendation in May 2026 [N5].
- The company’s clinical and manufacturing progress is regularly reported in public news and SEC filings, providing transparency on development milestones [N1][N2][N3][N4][N5].
Generated 2026-11-15
- S1 | 2026-03-12 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Century Therapeutics Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/century-therapeutics-reports-third-quarter-2026-financial-results
- N2 | 2026-11-12 | www.nasdaq.com | Century Therapeutics, Inc. Q3 Loss Declines | https://www.nasdaq.com/articles/century-therapeutics-inc-q3-loss-declines
- N3 | 2026-10-02 | www.nasdaq.com | Century Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data | https://www.nasdaq.com/articles/century-therapeutics-advances-cnty-813-toward-clinical-testing-new-easd-data
- N4 | 2026-09-10 | www.nasdaq.com | Century Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND Filing | https://www.nasdaq.com/articles/century-therapeutics-appoints-iecure-ceo-joseph-truitt-board-cnty-813-nears-ind-filing
- N5 | 2026-05-27 | www.nasdaq.com | Mizuho Initiates Coverage of Century Therapeutics (IPSC) with Outperform Recommendation | https://www.nasdaq.com/articles/mizuho-initiates-coverage-century-therapeutics-ipsc-outperform-recommendation
- N6 | 2025-12-09 | www.nasdaq.com | Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors | https://www.nasdaq.com/articles/why-fast-paced-mover-century-therapeutics-ipsc-great-choice-value-investors
- N7 | 2025-08-14 | www.nasdaq.com | Century Reports Flat Loss in Fiscal Q2 | https://www.nasdaq.com/articles/century-reports-flat-loss-fiscal-q2
- N8 | 2025-06-25 | www.nasdaq.com | Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum | https://www.nasdaq.com/articles/century-therapeutics-ipsc-attractively-priced-despite-fast-paced-momentum
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


